As far as I can tell, we are back where we were in November 2017, except the results are positive. Below is what LCT said they were planning to do.
The trial’s objectives are to confirm the most effective dose of NTCELL, to define any placebo component of the response, and to further identify the initial target Parkinson’s disease patient subgroup. If these objectives are met, the company will apply to Medsafe, the New Zealand Medicines and Medical Devices Safety Authority, for provisional consent in the last quarter of 2017 with a view toward treating paying patients in New Zealand in 2018.
Ann: NTCELL Parkinsons trial 2 year data analysis shows success, page-49
-
- There are more pages in this discussion • 68 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add 1AI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
-0.001(12.5%) |
Mkt cap ! $11.81M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.8¢ | 0.7¢ | $21.26K | 3.022M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 8514049 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 1168300 | 11 |
View Market Depth
| Last trade - 16.10pm 11/09/2024 (20 minute delay) ? |
| 1AI (ASX) Chart |